Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/17/2025

Management of Post-Chemotherapy Dizziness with Polatuzumab Vedotin

Diagnosis and Mechanism

  • The American Society of Clinical Oncology suggests that doxorubicin and potentially polatuzumab vedotin can cause central neurotoxicity affecting cerebellar Purkinje cells and vestibular integration pathways 1, 2
  • The alteration of the optocinetic reflex and low VOR/VVOR values suggest that cerebellar-vestibular integration is compromised 1, 2
  • It is highly probable that chemotherapy-induced neuropathy affects central vestibular signaling pathways 1, 2

Rehabilitation and Treatment

  • The American Academy of Otolaryngology-Head and Neck Surgery recommends a supervised vestibular rehabilitation program as fundamental 2, 4
  • Exercises for vestibular adaptation, gait training on variable surfaces, and moderate resistance exercises have demonstrated reduction in chemotherapy-induced neuropathy symptoms 2, 4
  • Duloxetina 30-60 mg/day is considered first-line for chemotherapy-induced neuropathy, with evidence of improvement in vestibular symptoms 4

Safety Measures and Pronóstico

  • Given the risk of falls due to vestibulo-spinal dysfunction, the American Geriatrics Society recommends using supportive and non-slip footwear, installing handrails, and ensuring adequate lighting 2
  • 15-40% of patients with chemotherapy-induced neuropathy have persistent symptoms, but most improve with time and rehabilitation 4
  • The sensation of walking on an incline may persist longer but typically improves with specific vestibular rehabilitation 2, 4